SkyePharma PLC announces Succession Plan

Market Wire, May, 2008

Succession Plan


LONDON, UK, 21 May 2008 - At its Annual General Meeting later today,
SkyePharma PLC (LSE: SKP) will announce that its Chief Executive
Officer, Frank Condella, intends to step down from his executive
position once the Company has completed its financial restructuring by
refinancing or renegotiating its convertible bonds. In accordance with
the Company's management succession plan Frank Condella will be
succeeded by Dr Ken Cunningham, currently Chief Operating Officer.
The Board is looking to announce definitive plans for refinancing or
renegotiating the convertible bonds once it has announced the results
of two further pivotal Phase III efficacy trials (SKY2028-3-004 and
SKY2028-3-001) of the Company's lead product for the treatment of
asthma, FlutiformTM.  As announced in the Interim Management Statement
on 19 May 2008, these trial results are anticipated this summer.
Mr Condella will continue on the Board as a Non-Executive Director of
the Company once the management changes have been effected.

Frank Condella, 53, was appointed CEO of SkyePharma in March 2006.
During his tenure, he has successfully led a major restructuring of the
Company's business and financial structure, including the sale of its
loss-making Injectable Business, the CRC financing, the Paul Capital
refinancing and an equity placing, all of which has enabled the Company
to continue to fund the development of FlutiformTM and other products
in the Company's pipeline. In addition, he has overseen the
outlicensing of FlutiformTM in each of the world's major territories -
to Kos Pharmaceuticals (now a subsidiary of Abbott) in the USA,
Mundipharma in Europe and, most recently, Kyorin in Japan - as well as
the Phase III development programme for FlutiformTM, for which positive
results have been reported in the first two of five Phase III clinical
trials.

Ken Cunningham, 55, is an experienced chief executive officer and has
worked closely with Frank Condella as Chief Operating Officer of
SkyePharma since April 2006.  Prior to joining SkyePharma, he was the
CEO of the specialty pharmaceutical company, Arakis Limited, which was
acquired by Sosei of Japan in 2005. During his career he has undertaken
a number of senior international management and clinical development
roles with Alza Corporation, Sequus Inc., GlaxoSmithKline and Warner
Lambert.

Commenting on today's announcement, Jeremy Scudamore, Non-Executive
Chairman of SkyePharma, said: "When Frank Condella joined SkyePharma in
early 2006, the Company needed significant restructuring and over the
past two years he and his team have refocused and reorganised the
Company such that it is now slimmer, fitter and well placed to grow in
the future.  The promise of the potential successful development of
FlutiformTM is being underpinned by the positive results from
the Phase III trials and Abbott's increased role in completing the
development and filing in the USA.  The Board would like to place on
record its thanks and congratulations to Frank for his efforts over the
past two years and we are delighted that he will be leading the Company
through its final restructuring phase, and thereafter will continue his
involvement with the Company as a Non-Executive Director."

Frank Condella said: "My time over the past two years at SkyePharma has
been a fascinating challenge and after a great deal of hard work by
all of our employees, I believe we are now strongly positioned to
achieve the objectives we have been working towards - the filing and
launch of FlutiformTM in the US and Europe, the continuing development
of our pipeline and, most importantly, the generation of profits and
value for shareholders. I look forward to working with Ken and the rest
of the Executive team over the coming months as we prepare FlutiformTM
for filing and complete the remaining tasks in the Company's
restructuring."


For further information please contact:

SkyePharma PLC                    Frank Condella     44 20 7491 1777
During office hours               Ken Cunningham
                                  Peter Grant

Financial Dynamics (UK Enquiries) David Yates        44 20 7831 3113
Outside office hours              Deborah Scott

Trout Group (US Enquiries)        Christine Labaree  1 617 583 1308
                                  Seth Lewis


About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of existing products to provide a clinical advantage
and life-cycle extension. The Company has twelve approved products in
the areas of oral, inhalation and topical delivery. The Group's
products are marketed throughout the world by leading pharmaceutical
companies.   For more information, visit  www.skyepharma.com 


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com